-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2894 Myelodysplastic Syndromes (MDS) with Erythroid Hyperplasia: Enumerating Blasts from Non-Erythroid Cell Compartment Improves the Risk Stratification of MDS with Excess of Blasts

Myelodysplastic Syndromes – Clinical Studies
Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II
Sunday, December 6, 2015, 6:00 PM-8:00 PM
Hall A, Level 2 (Orange County Convention Center)

Leonor Arenillas, MD1*, Xavier Calvo, MD1*, Mar Tormo, MD, PhD2, David Valcárcel, MD, PhD3, Elisa Luño, MD, PhD4*, Esther Alonso, MD5*, María Consuelo Cañizo, MD, PhD6*, Fernando Ramos, MD, PhD, MPH7*, Carmen Pedro, MD, PhD8*, Beatriz Arrizabalaga, MD9*, Alicia Bailén, MD10*, José María Raya, MD11*, María Teresa Ardanaz, MD12*, Guillermo Sanz, MD, PhD13 and Lourdes Florensa, MD, PhD1*

1Hematological Cytology Laboratory, Hospital del Mar, GRENTHE, IMIM (Hospital del Mar Research Institute), Barcelona, Spain
2Hospital Clínico Universitario de Valencia, Valencia, Spain
3Hospital Vall d'Hebrón, Barcelona, Spain
4Hematology, Hospital Universitario Central Asturias, Oviedo, Spain
5Hematology, Department of Pathology. Hospital de Bellvitge., Barcelona., Spain
6Hematology, Salamanca Universitary Hospital, Salamanca, Spain
7Hospital Universitario de León, León, Spain
8Hospital del Mar, Barcelona, Spain
9Hospital Universitario Cruces, Spanish MDS Cooperative Group, Bilbao, Spain
10Hospital Universitario Carlos Haya, Málaga, Spain
11Hospital Universitario de Canarias, Tenerife, Spain
12Hospital de Txagorritxu, Vitoria, Spain
13Hospital Universitario La Fe, Spanish MDS Cooperative Group, Valencia, Spain

Introduction: WHO classification of MDS is based on cytopenias, dysplasia, percentage of blasts in PB and BM, and cytogenetics.  IPSS-R establishes BM blast subgroups (2%,2-<5%,5%-10% and >10%) with independent impact in OS. Erythroid hyperplasia (≥50% of total BM cells) is common in MDS. Concerning MDS with expanded erythropoiesis, there is no consensus whether the proportion of BM blasts should be considered on the basis of all nucleated cells (approach-A) or in non-erythroid cells (approach-B).

Aim: To elucidate this issue, we reassess percentage of BM blasts of MDS with erythropoiesis 50% from the Spanish registry (RESMD), according to both definitions.

Methods: We performed a retrospective analysis of 507 primary MDS diagnosed according to WHO 2008. Proportion of red-cells was calculated in 500 nucleated cells. Erythroid hyperplasia was documented in 10.4% of patients from RESMD.

Results: Median age of presentation was 74years (25-94years) and 63% were males. Median follow-up was 29.4 months and median OS was 47.14 months. Table 1 shows distribution of WHO subtypes of the series according to both approaches. Of note, following WHO recommendations, RAEB-2 diagnosis was not possible; formally all of them were diagnosed with erythroleukemia. Distribution of patients according to IPSS-R blast-categories by both methods is shown in Table 2. It is noteworthy that 14/389pts (3.6%) with blasts <5% using approach-A were reclassified in 10-<20% category (RAEB-2) when the approach-B was applied. However, their survival did not differ significantly from those who remained in low-count blast categories. Using approach-A, IPSS-R blast categories discriminate significantly OS of blast subgroups <5% (0-2% vs. 2-<5%, 81 vs. 44 months, p=0.011). Nevertheless, categories with 5% blasts showed no differences (5-10% vs. 10-20%; 18 vs. 13 months, p=0.39). With approach-B, significant differences were observed among categories with <10% blasts (0-2% vs. 2-<5% vs. 5-10%; 82 vs. 65 vs. 41 months, p=0.032). However, as in IPSS-R, no differences were observed >10% (10-20% vs. >20%; 20 vs. 14 months, p=0.53). Figure 1.  Applying approach-A, significant differences in proportion of patients with high-risk karyotype defined by IPSS were seen between ≥5% blasts vs. <5%, but not between 5-<10% and 10-20%. Using approach-B, these differences appeared in 10% cut-off, without differences between 10-<20% and >20%. Therefore, high-risk patients (>10% blasts and high-risk cytogenetics) were better defined by the second method.

Conclusion: In agreement with WHO committee recommendations, these results suggest that there is no a uniform criteria for assessment of medullary blasts. Considering percentage of blasts on the basis of non-erythroid compartment might improve the classification and prognostication of MDS with ≥5% blast cells. However in low-blast count patients this approach could overestimate their risk.

image001.jpg

image002.jpg

 

image003.jpg

Disclosures: Valcárcel: Celgene Corporation: Honoraria , Membership on an entity’s Board of Directors or advisory committees , Speakers Bureau ; Amgen: Honoraria , Membership on an entity’s Board of Directors or advisory committees , Speakers Bureau ; Novartis: Honoraria , Membership on an entity’s Board of Directors or advisory committees ; GlaxoSmithKline: Membership on an entity’s Board of Directors or advisory committees , Speakers Bureau . Ramos: GlaxoSmithKline: Honoraria ; Janssen-Cilag: Honoraria , Membership on an entity’s Board of Directors or advisory committees ; Novartis: Consultancy , Honoraria ; Celgene Corporation: Consultancy , Honoraria , Membership on an entity’s Board of Directors or advisory committees , Research Funding ; Amgen: Consultancy , Honoraria .

*signifies non-member of ASH